<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04235933</url>
  </required_header>
  <id_info>
    <org_study_id>18C015</org_study_id>
    <nct_id>NCT04235933</nct_id>
  </id_info>
  <brief_title>A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects</brief_title>
  <official_title>A Phase I, Open-label Study to Evaluate the Pharmacokinetics, and Pharmacodynamics of a Single Dose of Tai Ai Injection in Healthy Adult Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to evaluate the pharmacokinetics, and pharmacodynamics of a single dose of Tai Ai injection&#xD;
      in healthy adult Chinese subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-max</measure>
    <time_frame>Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T-max</measure>
    <time_frame>Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57</time_frame>
    <description>Time to reach maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57</time_frame>
    <description>apparent terminal half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57</time_frame>
    <description>area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 extrapolated to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of AEs (adverse events).Through observing number of total AEs and number of subjects with AEs and other factors of AEs ，to evaluate the safety and tolerance of healthy subjects.</measure>
    <time_frame>Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57</time_frame>
    <description>Occurrence of all adverse events from signing of informed consent through end of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital Signs</measure>
    <time_frame>Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57</time_frame>
    <description>Through observing the normal and abnormal conditions of axillary temperature to evaluate the safety and tolerance of healthy subjects. Axillary temperature's normal ：≥36 and ≤37°C. Clinical significance of abnormal values as judged by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital Signs</measure>
    <time_frame>Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57</time_frame>
    <description>Through observing the normal and abnormal conditions of Pulse rate to evaluate the safety and tolerance of healthy subjects. Pulse rate's normal ：≥60 and ≤100. Clinical significance of abnormal values as judged by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital Signs</measure>
    <time_frame>Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57</time_frame>
    <description>Through observing the normal and abnormal conditions of Blood pressure (both systolic and diastolic) to evaluate the safety and tolerance of healthy subjects. systolic pressure 's normal： ≥90 and ≤139 ； diastolic pressure's normal ：≥60 and ≤89. Clinical significance of abnormal values as judged by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital Signs</measure>
    <time_frame>Day 0、Day 1、Day 2、Day 3、Day 5、Day 8、Day 15、Day 22、Day 29、Day 43、Day 57</time_frame>
    <description>Through observing the normal and abnormal conditions of respiration to evaluate the safety and tolerance of healthy subjects. respiration's normal ：≥10 and ≤24. Clinical significance of abnormal values as judged by the investigator</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tai Ai(RC18) 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>·Experimental: Tai Ai 80mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tai Ai(RC18) 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>·Experimental: RC18 160mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC18 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>·Experimental: RC18 240mg Injection: subcutaneous injection on abdomen; Intervention: Biological: RC18</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tai Ai(RC18) 80mg</intervention_name>
    <description>The patient received one treatment of RC18 80mg in the test group</description>
    <arm_group_label>Tai Ai(RC18) 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tai Ai(RC18) 160mg</intervention_name>
    <description>The patient received one treatment of RC18 160mg in the test group</description>
    <arm_group_label>Tai Ai(RC18) 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 240mg</intervention_name>
    <description>The patient received one treatment of RC18 240mg in the test group</description>
    <arm_group_label>RC18 240mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily signed the informed consent as applicable to participate in the study, age&#xD;
             18-55, inclusive, male: female=1:1;&#xD;
&#xD;
          2. Body mass index between 18.5-26 kg/m², inclusive, with a body weight ≥50 kg (male),&#xD;
             ≥45 kg (female);&#xD;
&#xD;
          3. Considered &quot;healthy&quot; by the investigator. Healthy status is defined by absence of&#xD;
             evidence of any active or chronic disease following a detailed medical and surgical&#xD;
             history, as well as a complete physical examination including vital signs, 12-lead&#xD;
             ECG, X-ray examination, infectious disease examination, peripheral blood cell count,&#xD;
             platelet aggregation and coagulation function, blood chemistry, urine routine and&#xD;
             stool routine ( include occult blood);&#xD;
&#xD;
          4. An understanding, ability, and willingness to fully comply with study procedures and&#xD;
             restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any hematological, digestive system, respiratory, cardiovascular, renal,&#xD;
             neurological, psychiatric disease, metabolic disorders or tumor, which could affect&#xD;
             the action, absorption, or disposition of the investigational product, or clinical or&#xD;
             laboratory assessments;&#xD;
&#xD;
          2. History of abnormal bleeding or coagulation disorders (e.g. easy bruising, gum&#xD;
             bleeding, prolonged bleeding after tooth extraction, joint hemorrhage; anemia in&#xD;
             recent 1 year caused by menorrhagia, postpartum hemorrhage, vitamin K deficiency,&#xD;
             haemorrhagic diseases caused by acquired coagulation factor antibodies, trauma or&#xD;
             post-operative bleeding, etc.);&#xD;
&#xD;
          3. Pregnant or lactating female during screening period; subjects and their partners did&#xD;
             not agree to take effective contraceptive measures (such as intrauterine devices,&#xD;
             contraceptives or condoms) throughout the study period and within 30 days after the&#xD;
             end of the visit period;&#xD;
&#xD;
          4. History of allergic to therapeutic or diagnostic protein products, allergic to two or&#xD;
             more drugs and/or non-drug factors; suffering from allergic diseases;&#xD;
&#xD;
          5. History of surgery within six months before signing the informed consent; Willing to&#xD;
             undergo surgery within two weeks after the end of the trial (including cosmetic&#xD;
             surgery, dental surgery, oral surgery, etc.);&#xD;
&#xD;
          6. Participated an investigational product in recent 3 months;&#xD;
&#xD;
          7. Current use of any prescription or over-the-counter (herbal, vitamins, or healthcare&#xD;
             products). Current use is defined as use within 14 days or PK equivalent of 5&#xD;
             half-lives, whichever is longer;&#xD;
&#xD;
          8. History of Bleeding or donated more than 400ml blood 3 months before screening period,&#xD;
             or plan to denote blood within 1 month after the trial;&#xD;
&#xD;
          9. Consume more tobacco or alcohol (≥14 units of alcohol per week: one standard unit&#xD;
             contains 14g of alcohol, equals to 360ml of beer, 45ml of 40% liquor or 150ml of wine;&#xD;
             smokers with more than 5 cigarettes per day.);&#xD;
&#xD;
         10. Consume excessive caffeine-containing beverages, foods that may affect drug metabolism&#xD;
             within four weeks before signing informed consent: coffee (≥1100 mL per day), tea&#xD;
             (≥2200 mL per day), cola (≥2200 mL per day), energy drinks (≥1100 mL per day),&#xD;
             chocolate (≥510 g per day);&#xD;
&#xD;
         11. Positive HIV, HBsAg, Hepatitis C virus, Tubercle Bacillus antibody screen;&#xD;
&#xD;
         12. Researchers believe that there are other factors that are not suitable for&#xD;
             participating in the experiment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhijun Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital Bengbu Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huan Zhou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital Bengbu Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Remegen，ltd.</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>264006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

